乙二醇-双(丁二酸N-羟基琥珀酰亚胺酯)二磺酸 | 167410-92-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 乙二醇-双(丁二酸N-羟基琥珀酰亚胺酯)二磺酸
• 英文名称: ethylene glycol bis(sulfosuccinimidyl succinate)
• 英文别名: Sulfo-EGS Crosslinker；1-[4-[2-[4-(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy-4-oxobutanoyl]oxyethoxy]-4-oxobutanoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid
• CAS: 167410-92-6
• 化学式: C₁₈H₂₀N₂O₁₈S₂
• 分子量: 616.491
• InChiKey: YDFAYDGRSWSLCT-UHFFFAOYSA-N

物化性质

• 密度：
  1.85

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  40
• 可旋转键数：
  17
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  306
• 氢给体数：
  2
• 氢受体数：
  18

文献信息

• Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
  申请人：YOSHIDA Kenji

  公开号：US20100111852A1

  公开（公告）日：2010-05-06

  Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

  提供了特异性结合于细胞表面表达的Claudin 3的单克隆抗体。本发明的抗体对于具有增强Claudin 3表达的癌症的诊断是有用的，如卵巢癌、前列腺癌、乳腺癌、子宫癌、肝癌、肺癌、胰腺癌、胃癌、膀胱癌和结肠癌。本发明提供了对这些癌症细胞具有细胞毒作用的单克隆抗体。公开了诱导Claudin 3表达细胞受损的方法以及通过与Claudin 3结合抗体接触Claudin 3表达细胞来抑制Claudin 3表达细胞增殖的方法。本申请还公开了癌症的诊断或治疗方法。
• [EN] CLEAVABLE NUCLEOTIDE ANALOGS AND USES THEREOF<br/>[FR] ANALOGUES NUCLÉOTIDIQUES CLIVABLES ET LEURS UTILISATIONS
  申请人：HARVARD COLLEGE

  公开号：WO2018102554A1

  公开（公告）日：2018-06-07

  Cleavable nucleotide analogs are provided. The nucleotide analog includes a nucleotide molecule attached to a cleavable moiety wherein the cleavable moiety comprises a protective group and/or a linker attached to a fluorophore. The cleavable moiety is linked to the oxygen atom of the 3'-OH of the pentose of the nucleotide molecule. The nucleotide analogs can be used in making polynucleotide molecules using template independent polymerases. The nucleotide analogs can act as reversible terminators during DNA sequencing by synthesis. The cleavage of the cleavable moiety restores a free 3'-OH functional group allowing growth of the polynucleotide molecule. The general structures as well as proposed synthetic schemes for the nucleotide analogs are also provided.

  可切割的核苷酸类似物已提供。该核苷酸类似物包括连接到可切割基团的核苷酸分子，其中可切割基团包括保护基团和/或连接到荧光团的连接物。可切割基团连接到核苷酸分子的五碳糖的3'-OH的氧原子。这些核苷酸类似物可用于使用模板无关聚合酶制备多核苷酸分子。这些核苷酸类似物在DNA合成测序过程中可作为可逆终止子。切割可切割基团恢复自由的3'-OH官能团，从而促进多核苷酸分子的生长。还提供了核苷酸类似物的一般结构以及拟议的合成方案。
• NON-HUMAN ANIMAL HAVING HUMAN CD3 GENE SUBSTITUTED FOR ENDOGENOUS CD3 GENE
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：US20180192623A1

  公开（公告）日：2018-07-12

  The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3ε, CD3δ, and CD3γ in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3ϵ, CD3δ, and CD3γ. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.

  本发明提供了一种基因改造的非人类动物，其基因组中缺乏至少一种或多种CD3基因，所述CD3基因来自包括内源CD3ε、CD3δ和CD3γ在内的一组中，并在功能上至少表达一种或多种人类CD3基因，所述人类CD3基因来自包括人类CD3ϵ、CD3δ和CD3γ在内的一组中。在本发明的基因改造的非人类动物中，成熟T细胞的分化和产生可以发生，并且包括T细胞在内的免疫活性细胞可以发挥其功能。本发明的基因改造的非人类动物使得可以在开发使用人类CD3介导的靶向药物的治疗剂和治疗方法时进行有效的评估和筛选。
• DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US20210301016A1

  公开（公告）日：2021-09-30

  The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

  本公开提供了多特异性抗原结合分子，其包括第一抗原结合基团和第二抗原结合基团，每个基团都能够结合CD3和CD137，但不能同时结合CD3和CD137；以及第三抗原结合基团，能够结合DLL3，最好是人源DLL3，它能更有效地诱导T细胞依赖性细胞毒性，同时规避其他多特异性抗原结合分子可能存在的不良毒性或副作用。本发明提供了多特异性抗原结合分子和制药组合物，可以作为活性成分治疗各种癌症，特别是与DLL3相关的癌症。
• Acryloyloxyethylphosphorylcholine Containing Polymer Conjugates and Their Preparation
  申请人：Charles Stephen A.

  公开号：US20100166700A1

  公开（公告）日：2010-07-01

  The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients.

  本发明涉及聚合物试剂及其共轭物，制备聚合物试剂和共轭物的方法，包括共轭物的制药组合物和使用聚合物共轭物的方法，其中包括将共轭物用于治疗患者的治疗方法。